Stock analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a note issued to investors on Thursday. The brokerage set a "hold" rating on the stock.
LadRx Stock Up ∞
Shares of NASDAQ:CYTR opened at $0.09 on Thursday. LadRx has a 12-month low of $0.05 and a 12-month high of $0.86.
Get
LadRx alerts:
About LadRx
(Get Rating)
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
Featured Articles
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
Stock analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a note issued to investors on Thursday. The brokerage set a "hold" rating on the stock.
斯托克新聞網的股票分析師在週四發給投資者的一份報告中開始報道LadRx(納斯達克代碼:Cytr-Get Rating)的股票。該經紀公司對該股設定了“持有”評級。
LadRx Stock Up ∞
Shares of NASDAQ:CYTR opened at $0.09 on Thursday. LadRx has a 12-month low of $0.05 and a 12-month high of $0.86.
週四,納斯達克的股價開盤報0.09美元。LadRx的12個月低點為0.05美元,12個月高位為0.86美元。
Get
LadRx
alerts:
About LadRx
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
LadRx公司是一家生物製藥研發公司,從事新型抗癌候選藥物的發現、研究和臨床開發。它專注於開發Linker激活藥物釋放(LADR)技術平臺,這是一個發現引擎,可以幫助創建一條抗癌分子的管道,在避免不可接受的全身毒性的同時,將高效藥物直接輸送到腫瘤。
Featured Articles
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
- 免費獲取StockNews.com關於LadRx的研究報告(Cytr)
- 企業產品合作夥伴是否得到公平評價?
- WhatsApp合作夥伴關係是否會提振MercadoLibre的收益?
- 2023年中型股可能翻一番
- 馬倫汽車簽署新合作夥伴後股價上漲
- REV集團引領專用車製造商走高
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收LadRx Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對LadRx和相關公司的最新新聞和分析師評級的每日簡要摘要。